Anti-VEGFs yield no visual improvement in eyes with fovea-involved macular atrophy

VANCOUVER, British Columbia β€” Anti-VEGF treatment did not improve vision in patients with fovea-involved macular atrophy, according to a poster presented at the Association for Research in Vision and Ophthalmology meeting.
β€œIn patients with macular atrophy that involves the fovea at baseline, anti-VEGF does not lead to visual recovery over 3 years,” author Weilin Song, BS, told
Song, from Case Western Reserve University School of Medicine and Cole Eye Institute, Cleveland, and colleagues undertook the study to investigate the variability in response to

Full Story β†’